Patent intelligence · US
US 10836702
Compositions and methods comprising resveratrol
Compositions and methods comprising resveratrol
Patent details — US 10836702
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 17, 2020
- Expiration
- Nov 12, 2040
- Applicant
- Biocogent, LLC
- Claims
- 3
- CPC classes
- A61K, A61K2800/10, A61K31/618, A61K8/37
Quick answer
US 10836702 (Compositions and methods comprising resveratrol) is held by Biocogent, LLC. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biocogent, LLC
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K2800/10, A61K31/618, A61K8/37
More from Biocogent, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12351581
Compounds for FGFR inhibition
granted -
US 12281122
PI3K inhibitors
granted -
US 11718576
Compositions and methods comprising resveratrol
granted -
US 11339112
Compositions and methods comprising resveratrol
granted -
US 10449129
Encapsulates of salicylic acid and polysalicylic acid derivatives
granted -
US 10301248
Compositions and methods comprising resveratrol
granted -
US 6610295
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
expired
Frequently asked questions
What is US patent 10836702?
US 10836702 (Compositions and methods comprising resveratrol) is held by Biocogent, LLC. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10836702?
Biocogent, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 10836702 expire?
Our index shows an expiration date of Nov 12, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.